ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD) a clinical-stage BioPharma firm developing medication candidates to cure Alzheimer’s disease, pain, CNS diseases, and cancers, reported that it will present full PART A data and initial PART B results from the underway Phase 2a clinical study of ANAVEX 2-73 at the Clinical Trials on Alzheimer’s Disease conference to be held in Barcelona from November 5 to November 7, 2015. The company reported that the late-breaking oral lecture will be presented by the study’s Principal Investigator, Mr. Stephen Macfarlane, FRANZCP, Associate Professor and Director, Aged Psychiatry at Caulfield Hospital in Australia.
The details
The multicenter Phase IIa clinical study of ANAVEX 2-73 comprises of two distinct parts and a total of thirty-two subjects suffering from mild-to-moderate Alzheimer’s. Anavex stated that PART A is a simple randomized, two-period, cross-over, open-label, adaptive study lasting up to thirty-six days for each subject. On the other hand PART B of Phase 11a clinical study is an open-label extension lasting for an additional fifty-two weeks.
Study objectives
The primary goal of the study is to determine the maximum tolerated dose of experimental medication ANAVEX 2-73. Anavex reported that secondary trial goals include exploratory cognitive efficiency using MMSE, dose response, Cogstate and electroencephalographic activity, including EEG/ERP and bioavailability, as well as the relationship of lead drug ANAVEX 2-73 as an add-on medication to donepezil. Additional information pertaining to the underway Phase 2a clinical study can be accessed on the site of the U.S. National Institutes of Health clinical studies database.
ANAVEX 2-73
It is an investigational therapy in the Phase 2a study and is Anavex’s lead investigational cure for fatal Alzheimer’s disease. It target areas are sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding, tau, inflammation and beta amyloid. Preclinical results suggest that experimental drug has the potential to halt, reverse or prevent the course of Alzheimer’s disease.
